BioCryst Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
BioCryst Pharmaceuticals's earnings have been declining at an average annual rate of -8%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 45.7% per year.
Key information
-8.0%
Earnings growth rate
0.3%
EPS growth rate
Biotechs Industry Growth | 12.9% |
Revenue growth rate | 45.7% |
Return on equity | n/a |
Net Margin | -30.0% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BioCryst Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 413 | -124 | 250 | 0 |
30 Jun 24 | 382 | -146 | 235 | 0 |
31 Mar 24 | 355 | -209 | 225 | 0 |
31 Dec 23 | 331 | -227 | 214 | 0 |
30 Sep 23 | 318 | -236 | 200 | 0 |
30 Jun 23 | 307 | -243 | 186 | 0 |
31 Mar 23 | 290 | -226 | 173 | 0 |
31 Dec 22 | 271 | -247 | 159 | 0 |
30 Sep 22 | 238 | -193 | 152 | 0 |
30 Jun 22 | 204 | -210 | 143 | 0 |
31 Mar 22 | 188 | -194 | 131 | 0 |
31 Dec 21 | 157 | -184 | 119 | 0 |
30 Sep 21 | 114 | -227 | 97 | 0 |
30 Jun 21 | 79 | -214 | 87 | 0 |
31 Mar 21 | 32 | -209 | 74 | 0 |
31 Dec 20 | 18 | -183 | 63 | 0 |
30 Sep 20 | 54 | -125 | 52 | 0 |
30 Jun 20 | 49 | -116 | 47 | 0 |
31 Mar 20 | 48 | -115 | 42 | 0 |
31 Dec 19 | 49 | -109 | 37 | 0 |
30 Sep 19 | 12 | -134 | 31 | 0 |
30 Jun 19 | 12 | -126 | 27 | 0 |
31 Mar 19 | 23 | -107 | 33 | 0 |
31 Dec 18 | 21 | -101 | 30 | 0 |
30 Sep 18 | 22 | -93 | 30 | 0 |
30 Jun 18 | 29 | -79 | 25 | 0 |
31 Mar 18 | 20 | -77 | 14 | 0 |
31 Dec 17 | 25 | -66 | 14 | 0 |
30 Sep 17 | 30 | -51 | 12 | 0 |
30 Jun 17 | 29 | -47 | 11 | 0 |
31 Mar 17 | 31 | -47 | 11 | 0 |
31 Dec 16 | 26 | -55 | 11 | 0 |
30 Sep 16 | 22 | -69 | 11 | 0 |
30 Jun 16 | 25 | -72 | 11 | 0 |
31 Mar 16 | 46 | -51 | 12 | 0 |
31 Dec 15 | 48 | -43 | 13 | 0 |
30 Sep 15 | 49 | -37 | 12 | 0 |
30 Jun 15 | 41 | -31 | 11 | 0 |
31 Mar 15 | 17 | -50 | 10 | 0 |
31 Dec 14 | 14 | -45 | 7 | 0 |
30 Sep 14 | 19 | -39 | 7 | 0 |
30 Jun 14 | 18 | -38 | 7 | 0 |
31 Mar 14 | 17 | -36 | 6 | 0 |
31 Dec 13 | 17 | -30 | 6 | 0 |
Quality Earnings: BCRX * is currently unprofitable.
Growing Profit Margin: BCRX * is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BCRX * is unprofitable, and losses have increased over the past 5 years at a rate of 8% per year.
Accelerating Growth: Unable to compare BCRX *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BCRX * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.1%).
Return on Equity
High ROE: BCRX *'s liabilities exceed its assets, so it is difficult to calculate its Return on Equity.